During the last session, Vertex Pharmaceuticals, Inc (NASDAQ:VRTX)’s traded shares were 0.89 million, with the beta value of the company hitting 0.44. At the end of the trading day, the stock’s price was $468.85, reflecting an intraday loss of -2.23% or -$10.68. The 52-week high for the VRTX share is $519.88, that puts it down -10.88 from that peak though still a striking 19.41% gain since the share price plummeted to a 52-week low of $377.85. The company’s market capitalization is $120.40B, and the average intraday trading volume over the past 10 days was 1.32 million shares, and the average trade volume was 1.58 million shares over the past three months.
Vertex Pharmaceuticals, Inc (VRTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.03. VRTX has a Sell rating from 0 analyst(s) out of 16 analysts who have looked at this stock. 5 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 11 recommend a Buy rating for it.
Vertex Pharmaceuticals, Inc (NASDAQ:VRTX) trade information
Vertex Pharmaceuticals, Inc (VRTX) registered a -2.23% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.23% in intraday trading to $468.85, hitting a weekly high. The stock’s 5-day price performance is 2.01%, and it has moved by 3.84% in 30 days. Based on these gigs, the overall price performance for the year is 16.43%. The short interest in Vertex Pharmaceuticals, Inc (NASDAQ:VRTX) is 4.03 million shares and it means that shorts have 2.78 day(s) to cover.
The consensus price target of analysts on Wall Street is $460, which implies a decrease of -1.92% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $420 and $545 respectively. As a result, VRTX is trading at a discount of -16.24% off the target high and 10.42% off the low.
While earnings are projected to return 4181.59% in 2025.
VRTX Dividends
Vertex Pharmaceuticals, Inc is due to release its next quarterly earnings on 2025-May-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Vertex Pharmaceuticals, Inc (NASDAQ:VRTX)’s Major holders
Vertex Pharmaceuticals, Inc insiders own 0.15% of total outstanding shares while institutional holders control 97.64%, with the float percentage being 97.78%. CAPITAL WORLD INVESTORS is the largest shareholder of the company, while 2259.0 institutions own stock in it. As of 2024-06-30, the company held over 26.71 million shares (or 10.3479% of all shares), a total value of $12.52 billion in shares.
The next largest institutional holding, with 22.98 million shares, is of VANGUARD GROUP INC’s that is approximately 8.9018% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $10.77 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Vertex Pharmaceuticals, Inc (VRTX) shares are GROWTH FUND OF AMERICA and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Mar 31, 2025 indicates that GROWTH FUND OF AMERICA owns about 11.34 shares. This amounts to just over 4.42 percent of the company’s overall shares, with a $5.32 billion market value. The same data shows that the other fund manager holds slightly less at 8.11, or about 3.16% of the stock, which is worth about $3.8 billion.
